Proposal to amend the listing of various pharmaceuticals in the Infections group
We apologise for any confusion the consultation document may have caused due to lack of clarity where the proposed changes were to occur, i.e. Community or Hospital. The updated consultation document now defines whether the changes are for Section B (i.e. community) or Section H (i.e. in hospital). Sorry for the confusion this has caused.
PHARMAC is seeking feedback on a proposal to amend the restrictions applying to certain pharmaceuticals in the Infections – Agents for Systemic Use Group in Section B and Part II of Section Hof the Pharmaceutical Schedule.
As part of PHARMAC’s work on developing Section H the Anti-Infective Subcommittee of PTAC recommended amending the restrictions applying to several products in the Infections - Agents for Systemic Use therapeutic group. The Subcommittee considered these pharmaceuticals at its meetings of 22 February 2012 and 1 March 2012 and 13 December 2012. The relevant minutes can be found at the following link.
The proposal would affect the following products or groups and apply to both Section B and Part II of Section H as applicable.
- Cefazolin sodium
- Ceftriaxone sodium
- Gentamicin sulphate
- Vancomycin hydrochloride
- Tenofovir disoproxil fumarate
- Pegylated interferon alpha-2a
Full details of the proposal can be found on the following pages.
All proposed changes would occur 1 July 2013.
PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Thursday, 18 April 2013 to:
Senior Therapeutic Group Manager
PO Box 10 254
Fax: 04 460 4995
All feedback received before the closing date will be considered by PHARMAC’s Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like withheld.